Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been ...
The plaintiff is represented by Robbins Geller, which has extensive experience in prosecuting investor class actions including actions involving financial fraud. You can view a copy of the complaint ...
DUBLIN 18, Ireland (AP) — Icon PLC (ICLR) on Wednesday reported fourth-quarter net income of $260 million. The Dublin 18, Ireland-based company said it had profit of $3.16 per share. Earnings, ...
Highlights Net business wins in the quarter of $2,413 million; a net book to bill in the quarter of 1.18. Full year net business wins of $9,974 million; a net book to bill of 1.20. Closing ...
Icon PLC (ICLR) came out with quarterly earnings of $3.43 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $3.46 per share a year ago. These figures are ...
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...
Icon plc has launched a new buyback program to repurchase up to $750 million of its shares. The total value of the authorized share repurchase is now up to $1 billion, the healthcare intelligence and ...
For the full year 2024, ICON reported revenue of $8.28 billion, a 2% increase YoY. Adjusted diluted EPS rose 9.5% to $14.00. Looking ahead, the company reaffirmed its 2025 financial guidance, ...
Robbins LLP reminds stockholders that a class action was filed on behalf of all purchasers of ICON PLC (NASDAQ: ICLR) ordinary shares between July 27, 2023 and October 23, 2024. ICON is a ...
NEW YORK, Feb. 14, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against ICON plc (NASDAQ: ICLR) and certain of its senior ...
The market expects Icon PLC (ICLR) to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...
Clinical research conductor ICON Plc downplayed impacts from demand softness from the pharmaceutical and biotechnology ...